Which one is better, Ado-trastuzumab emtansine or dual-targeting?

Ado-trastuzumab emtansine and dual-targeted therapy are both drugs used to treat HER2-positive breast cancer, but their mechanisms and effects are slightly different.

Trastuzumab is a drug that combines a monoclonal antibody targeting HER2 with a cytotoxin. It can directly act on HER2-positive tumor cells and kill these cancer cells by releasing cytotoxins. Trastuzumab is typically used in patients whose disease has progressed despite other HER2-targeted therapies, such as trastuzumab. Studies have shown that trastuzumab has significant advantages in prolonging progression-free survival and overall survival.

Dual-targeted therapy refers to a treatment strategy that simultaneously targetsHER2 and ER (estrogen receptor). It usually involves using a combination of HER2-targeted drugs (such as trastuzumab) and endocrine therapy (such as selective estrogen receptor modulators or estrogen antagonists). The goal of dual-targeted therapy is to simultaneously inhibit the HER2 and ER signaling pathways to more effectively control the growth and metastasis of breast cancer. Studies have shown that dual-targeted therapy has good efficacy in the treatment of HER2-positive breast cancer.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.